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Recently, enzyme replacement therapy involving a recombinant human IDUA (laronidase) for MPS I was developed, and clinical studies revealed that it improves the forced vital capacity, 6-min walk test distance, sleep apneal hypopnea, mean maximal range of motion on shoulder flexion and elbow extension, with decreased hepatosplenomegaly and urinary GAG excretion. 4, 5) However, its efficacy as to skeletal and cartilage disorders is unknown, but is under investigation.
For determination of the effect of laronidase, not only clinical studies but also basic studies involving cultured cells are very important. However, there have been few reports concerning such studies. 6) In this study, we investigated the uptake of laronidase by cultured fibroblasts from a patient with MPS I, and examined its morphological effect. Furthermore, we compared the uptake of laronidase by cultured mouse osteoblasts with that by cultured mouse fibroblasts.
MATERIALS AND METHODS
Compounds Laronidase was purchased from Genzyme Japan (Tokyo, Japan). 4-Methylumbelliferyl-a-L-iduronide was purchased from Toronto Chemicals (North York, Canada).
Cell Culture Cultured skin fibroblasts from a patient with MPS I (F17), a healthy subject (F592), and a wild-type mouse (F665) were established and cultured in Ham's F-10 medium (Invitrogen, Carlsbad, CA, U.S.A.) containing 10% fetal calf serum for human fibroblasts and 20% fetal calf serum for mouse fibroblasts, at 37°C under 5% CO 2 . The ethical committee of our institute approved the study involving the human cells (No. 1908) and informed consent of the patient and the control subject was obtained. Mouse osteoblasts (MC3T3-E1; ATCC, Manassas, VA, U.S.A.) were cultured in a-MEM (Nacalai Tesque, Kyoto, Japan) containing 10% fetal calf serum, at 37°C under 5% CO 2 .
Assaying of IDUA Activity and Protein Determination The IDUA activity of laronidase was measured fluorometrically, essentially according to the method of Hopwood.
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Briefly, the assay for IDUA was performed in 50 mmol/l formate buffer, pH 3.5, containing 1.0 mmol/l 4-methylumbelliferyl-a-L-iduronide at 37°C for 10 min (total volume: 100 ml). The reaction was stopped by adding 900 ml of 0.2 mol/l glycine buffer, pH 10.7 For determination of intracellular IDUA activity, cell homogenates were allowed to react with 0.8 mmol/l 4-methylumbelliferyl-a-L-iduronide in 80 mmol/l formate buffer, pH 3.5, containing 9.6 mmol/l D-saccharic acid 1,4-lactone, at 37°C for 30 min.
Examination of the Effect of Laronidase on Cultured Human MPS I Cells To examine the uptake of laronidase by human fibroblasts, laronidase was added to the culture medium of fibroblasts from a patient with MPS I (F17) and a healthy subject (F592) to give concentrations of 0, 0.10, 1.0, and 5.0 mg/ml. For examination of the inhibitory effect of mannose 6-phosphate (M6P) on the cellular uptake of laronidase, fibroblasts were cultured in medium containing 5.0 mg/ml laronidase in the presence of 5.0 mmol/l M6P. After 2 d culture, the cells were harvested mechanically, washed three times with phosphate-buffered saline (PBS), pH 7.4, and then collected as a pellet by centrifugation. An appropriate amount of water was then added to the pellet and the cells were sonicated, the resulting homogenate being used for the IDUA assay and protein determination.
Processing of the incorporated laronidase was examined by means of Western blotting. F17 and F592 cells were cultured in medium containing 5.0 mg/ml laronidase in the presence or absence of 5.0 mmol/l M6P for 2 d. Then, cell homogenates (each 20 mg) were prepared and solubilized in sodium dodecylsulfate (SDS) sample buffer (30 mmol/l Tris-HCl, pH 6.8, 2% SDS, 15% glycerol and 2.5% b-mercaptoethanol), separated on 4-20% Tris-glycine polyacrylamide gels (PAG mini; Daiichi Pure Chemical Co., Tokyo, Japan), and then electrotransferred to polyvinylidene difluoride (PVDF) Immobilon-P membranes (Millipore Co., Bedford, MA, U.S.A.). The blots were blocked in Tris-buffered saline (TBS: 50 mmol/l Tris-HCl, pH 7.4, 100 mmol/l NaCl) containing 5% skim milk for 30 min at room temperature. Then, the blots were reacted with 1 : 500 diluted rabbit polyclonal antibodies against laronidase, washed in TBS three times, and reacted with peroxidase-conjugated donkey antirabbit secondary antibodies (Amersham Pharmacia Biotech, Arlington Heights, IL, U.S.A.) for 1 h at room temperature. Finally, the blots were washed in TBS and developed with ECL (Amersham Pharmacia Biotech) as a chemiluminescent substrate on Hyperfilm TM ECL (Amersham Pharmacia Biotech). A preliminary study had revealed that the anti-laronidase antibodies could detect 4 ng or more of laronidase (data not shown).
To investigate the localization of laronidase incorporated into cells, human fibroblasts (F17 and F592) were cultured on a Lab-Tek chamber slide (Nunc, Naperville, IL, U.S.A.) in medium containing 5.0 mg/ml laronidase for 2 d. Then, the cells were fixed with 4% paraformaldehyde in PBS, pH 7.4, for 5 min, followed by blocking with 4% Block Ace (Dainippon Sumitomo Pharma, Tokyo, Japan) in PBS for 1 h. The cells were then reacted with the anti-laronidase antibodies and mouse monoclonal anti-lysosomal-associated membrane protein-1 (LAMP-1) antibodies (1 : 100 diluted; IgG isotype, Southern Biotechnology, Birmingham, AL, U.S.A.) for 1 h. After washing, they were reacted for 1 h with Alexa Fluor 594-conjugated goat anti-rabbit IgG antibodies (1 : 500 diluted; Molecular Probes, Eugene, OR, U.S.A.) and Alexa Fluor 488-conjugated goat anti-mouse IgG antibodies (1 : 500 diluted; Molecular Probes). The stained cells were observed under a microscope (Axiovert 100 M; Carl Zeiss, Oberkochen, Germany) equipped with a confocal laser scanning imaging system (LSM510; Carl Zeiss).
A morphological study was performed to examine the effect of laronidase on the degradation of GAGs accumulated in cultured fibroblasts from a patient with MPS I (F17). The cells were cultured on a chamber slide (Miles Laboratories, Naperville, IL, U.S.A.) in medium containing 5.0 mg/ml laronidase for 2 d. The cells were then trypsinized, fixed in PBS containing 2.5% glutaraldehyde and 2% paraformaldehyde for 30 min, postfixed in 2% osmium tetraoxide, dehydrated through a graded ethanol series, and then embedded in Epon 812. Ultrathin sections were mounted on copper grids, contrasted with uranyl acetate and lead citrate, and finally examined under an electron microscope (Hitachi H-7100; Hitachi, Tokyo, Japan).
8)

Comparison of Uptake of Laronidase by Cultured Mouse Osteoblasts and Fibroblasts
To compare the uptake of laronidase by cultured mouse osteoblasts and fibroblasts, MC3T3-E1 cells as representatives of the bone system and F665 cells as ones of the connective tissue system were cultured in medium containing laronidase at the concentration of 0, 0.10, 1.0, or 5.0 mg/ml. Furthermore, the cells were cultured in medium containing 5.0 mg/ml laronidase in the presence of 5.0 mmol/l M6P or 5.0 mmol/l mannose (Man). After 2 d culture, the cells were harvested, and then the IDUA assays and protein determination were performed. Furthermore, Western blotting was performed using cells which had been cultured in medium containing 5.0 mg/ml laronidase in the presence of 5.0 mmol/l M6P or 5.0 mmol/l Man for 2 d as samples, according to the method described above.
Statistical Analysis To compare the uptake of laronidase by MC3T3-E1 cells and F665 cells, statistical comparisons were performed by means of Student's t-test under the conditions of a two-tailed distribution and two-sample equal variance.
RESULTS
Biochemical Characterization of Laronidase
The enzymological analysis revealed that the specific activity of laronidase was 7.4 mmol/h/mg. The results of LineweaverBurk plot for laronidase are shown in Fig. 1 . The K m value was 0.22 mmol/l.
Uptake of Laronidase by Cultured Human Fibroblasts Human MPS I (F17) and wild-type (F592) fibroblasts were cultured in medium containing the indicated concentrations of laronidase for 2 d. Then, the cells were harvested and the intracellular IDUA activity was determined. As shown in Table 1 , the enzyme activity increased dose-dependently in both F17 and F592 cells. The uptake of laronidase by these cells was strongly inhibited in the presence of 5.0 mmol/l M6P in the culture medium.
Intracellular Processing of Laronidase Incorporated into Cultured Human Fibroblasts
To examine the intracellular processing of laronidase incorporated into cultured human fibroblasts, F17 and F592 cells were cultured in medium containing 5.0 mg/ml laronidase in the presence or absence of 5.0 mmol/l M6P for 2 d, and then Western blot analysis of laronidase was performed. The results are shown in Fig. 2 . Laronidase gave an 83 kDa (precursor form) band before incorporation into the cells, and then was processed into 76 and 69 kDa mature components after incorporation. The results also revealed that M6P strongly inhibited the incorporation of laronidase into the cells. In this analysis, no bands corresponding to internal IDUA components could be detected not only for F17 cells but also for F592 cells. As mentioned under Materials and Methods, the antibodies to laronidase could not recognize less than 4 ng of laronidase components. Thus the reason why the internal IDUA components could not be detected not only for F17 cells but also for F592 cells have been the low sensitivity of the antibodies, because the apparent difference in IDUA activity between these cells could be detected when highly sensitive enzyme assaying was performed.
Biodistribution of Laronidase Incorporated by Cultured Fibroblasts
To investigate the biodistribution of the laronidase incorporated into the cultured fibroblasts, double staining for laronidase and LAMP-1 was performed. Granular staining for laronidase was observed after incorporation of the enzyme, the location being identical to that for LAMP-1, marker of lysosomes (Fig. 3) .
Morphological Effect of Laronidase on MPS I Fibroblasts
The electron microscopic study revealed the existence of numerous cytoplasmic inclusion bodies in the cultured fibroblasts from the patient with MPS I (F17) (Fig. 4a) , and an apparent decrease in the number of cytoplasmic inclusion bodies was observed after 2 d culture of the cells in medium containing 5.0 mg/ml laronidase (Fig. 4b) .
Comparison of the Uptake of Laronidase by Cultured Mouse Osteoblasts with That by Cultured Mouse Fibroblasts The uptake of laronidase by cultured mouse osteoblasts (MC3T3-E1) was compared with that by cultured mouse fibroblasts (F665). As shown in Table 2 , the intracellular IDUA activity increased dose-dependently in both MC3T3-E1 and F665 cells. When laronidase was added to the medium at a low concentration, 0.10 mg/ml, there was no difference in the uptake between them. However, the increase in the enzyme activity was always lower in MC3T3-E1 cells than in F665 ones when laronidase was added to the medium at the concentration of 1.0 mg/ml or more. The statistical examination revealed that there was a significant difference in the uptake of laronidase between MC3T3-E1 cells and F665 cells (pϽ0.01). The uptake of the enzyme by MC3T3-E1 cells was strongly inhibited by the addition of 5.0 mmol/l M6P to the culture medium, but moderately inhibited by the addition of 5.0 mmol/l Man, as was the case in F665 cells.
Immunoblotting analysis to examine the processing of laronidase after incorporation into cells revealed that the 83 kDa precursor enzyme was processed into the mature components in both cultured mouse osteoblasts and fibroblasts, although the 69 kDa component was the major one in MC3T3-E1 cells. The results showed that M6P strongly inhibited the incorporation of laronidase into the cells and that Man moderately did so. The results also revealed that the uptake of laronidase was lower in MC3T3-E1 cells than in F665 cells (Fig. 5) . 
Fig. 3. Immunocytochemical Analysis of Laronidase Incorporated into Cultured Human Fibroblasts
Human fibroblasts (F17 and F592) were cultured in medium containing 5.0 mg/ml laronidase (ϩ) for 2 d, and then double staining of the cells was carried out using polyclonal antibodies for laronidase (IDUA, red) and monoclonal antibodies for LAMP-1 (LAMP-1, green). F17 and F592 cells which were cultured in the medium not containing laronidase (Ϫ) were used as controls. Images obtained with these two fluorescent probes, phase-contrast and immunofluorescence ones, respectively, overlapped (yellow; Merge/Phase contrast). Barsϭ50 mm. 6) In this study, we examined the effect of laronidase, which is now available for therapy for MPS I, on cultured MPS I fibroblasts biochemically and morphologically.
The results of the present analyses showed that the precursor form of the enzyme could be incorporated into MPS I fibroblasts dose-dependently mainly via M6P receptors. The incorporated enzyme was processed into the mature components, which were transported to lysosomes, the pathological findings being improved. These results suggest that enzyme replacement therapy should be effective for improving various manifestations due to disorders of connective tissue disorders.
However, previous studies on enzyme replacement therapy involving a canine model of MPS I revealed that a recombinant IDUA could decrease the storage of GAGs in the liver, kidneys, spleen, lymph nodes, adrenals, and lungs, but not in cartilage. 9, 10) As far as we know, the clinical improvement of disorders of skeletal and cartilage tissues on enzyme replacement therapy with the presently available recombinant enzymes is unknown, but is under investigation. 11) Our experimental data for cultured mouse cells revealed that laronidase was incorporated into osteoblasts as well as into fibroblasts mainly via M6P receptors and partially via Man ones, which play an important role in the uptake of lysosomal enzymes by macrophages. But the uptake of the enzyme by osteoblasts was apparently lower than that by fibroblasts when the cells were cultured in medium containing 1.0 mg/ml laronidase or more. This must be one of the reasons why laronidase is not so effective for skeletal disorders in MPS I. Also, the anatomical characteristics of osteoblasts surrounded by the matrix in skeletal and cartilage tissue must cause the low uptake of the enzyme in vivo.
In conclusion, we examined the uptake of laronidase by cultured human MPS I fibroblasts and its effect on the cleavage of accumulated substrates morphologically. Furthermore, we investigated the uptake of laronidase by cultured mouse osteoblasts in comparison with that by cultured mouse fibroblasts, and revealed that laronidase could be incorporated into the both the osteoblasts and fibroblasts mainly via M6P receptors, but that uptake of the enzyme by the former was lower than that by the latter.
To improve enzyme replacement therapy for skeletal disorders in MPS I, the administration of a high dose of the enzyme or the development of a recombinant IDUA containing many M6P residues is required.
